Neurogenic bladder in children: use of feed-back tools during standard treatment with anticholinergics.

Neurogenic bladder in children: use of feed-back tools during standard treatment with anticholinergics. - Home bladder pressure measurement.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON39539

Enrollment

100

Registered

2013-07-11

Start date

2014-09-01

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bladder sphincter disorder Neurogenic bladder

Interventions

Group 1: Standard treatment of oral or intravesical anticholinergics and CIC, yearly visits to the outpatient clinic, and yearly quality of life questionnaire, and urine volume twice a month, acces

Eligibility

Age

2 Years to 17 Years

Inclusion criteria

Inclusion criteria: * Children 0-18 years * Already treated at our centre with CIC and anticholinergics or new patients at our centre who need CIC and anticholinergic treatment

Exclusion criteria

Exclusion criteria: * Non-neurogenic BSD (e.g. urethral valves) * Neurogenic bladder after bladder augmentation * Inability of patient/ caregivers to understand the instructions on how to perform CIC * Inability of patient/ caregivers to understand the instructions on the home bladder pressure measurements * Inability of patient/caregivers to understand the instructions on application of the anticholinergics intravesical * Inability of patient/ caregivers to understand the instructions on the use of the website.

Design outcomes

Primary

Measure	Time frame
Reduction in unscheduled hospital visits (due to bladder and kidney problems).	—

Secondary

Measure	Time frame
- Preservation of bladder and renal function and quelity of life. - Patient compliance to medication and CIC. - Incidence and severity of bladder dysfunction related symptoms (incontinence and overactivity related discomfort). - Time of detection and frequency of tethered cord or other new neurological damage. - Time of detection and frequency of urinary tract infection (UTI). - Anticholinergic application form. - Actual dose of medication, determined from the answers on the questionnaires and answers on the specific question on use of medication in the webtool. - Actual CIC frequency. - Patient satisfaction with treatment. - Workload treatment team. - Visits to website (indicator for motivation).	—

Measure

Time frame

- Preservation of bladder and renal function and quelity of life. - Patient compliance to medication and CIC. - Incidence and severity of bladder dysfunction related symptoms (incontinence and overactivity related discomfort). - Time of detection and frequency of tethered cord or other new neurological damage. - Time of detection and frequency of urinary tract infection (UTI). - Anticholinergic application form. - Actual dose of medication, determined from the answers on the questionnaires and answers on the specific question on use of medication in the webtool. - Actual CIC frequency. - Patient satisfaction with treatment. - Workload treatment team. - Visits to website (indicator for motivation).

—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)